Current Event-Free Survival After Sequential Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia

Documenti analoghi

• Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy
  di: Quintás-Cardama, Alfonso, et al.
  Pubblicazione: (2011)
• Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia
  di: Eghtedar, Alireza, et al.
  Pubblicazione: (2013)
• Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies
  di: Verma, Dushyant, et al.
  Pubblicazione: (2011)
• Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy
  di: Pemmaraju, Naveen, et al.
  Pubblicazione: (2012)
• Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
  di: Jain, Preetesh, et al.
  Pubblicazione: (2013)